Tarsons Products Limited has informed the Exchange about change in Management
TARSONS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tarsons Products Limited has announced three changes to its Board, all effective 4th August 2025. Dr. Monjori Mitra, a pediatrician with 24 years of experience, has been appointed as a Non-Executive Independent Director for a 5-year term, subject to shareholder approval. Mr. Suresh Eshwara Prabhala resigned as a Nominee Director (representing investor Clear Vision Investment Holdings Pte Ltd) citing personal reasons, but has simultaneously been re-appointed as a Non-Executive Non-Independent Director. Mr. Ramanathan Subramanian Arun Kumar, a financial services veteran with prior CFO roles at a sovereign wealth fund and senior positions at PineBridge and J.P. Morgan, has been appointed as the replacement Nominee Director for Clear Vision Investment Holdings. All appointments are subject to shareholder approval.
These are routine board-level changes with no impact on operations or financials. The addition of a medical professional as Independent Director strengthens domain expertise, while the nominee director swap is an investor-driven replacement rather than a governance concern. Shareholders are unlikely to see any material effect on the stock from these changes.